ライフサイエンスコーパス: FGF21

1 tabolic hormone fibroblast growth factor 21 (FGF21).

2 d expression of fibroblast growth factor 21 (FGF21).

3 in-6 (IL-6) and fibroblast growth factor 21 (FGF21).

4 FA flux from adipose tissue to the liver via FGF21.

5 he enzyme that cleaves and inactivates human FGF21.

6 circulating levels and hepatic expression of FGF21.

7 co-receptor, which suggests a resistance to Fgf21.

8 ted by using a neutralizing antibody against FGF21.

9 on a recently identified natural substrate, FGF21.

10 arkers of tissue breakdown--as predictors of FGF21.

11 xpression and secretion of the known myokine FGF21.

12 ive damage, compared with mice not receiving FGF21.

13 , via a heart-brown fat cross-talk involving FGF21.

14 uction in hepatic Fgf21 mRNA and circulating FGF21.

15 chastically increasing hepatic expression of Fgf21.

16 togenic hormone fibroblast growth factor 21 (FGF21), a member of the endocrine FGF subfamily, is expr

17 Fibroblast growth factor 21 (FGF21), a peptide hormone with pleiotropic effects on ca

18 findings identify a mechanistic link between FGF21, a long-known marker of mitochondrial disease, and

19 size at birth but show a marked increase in FGF21 accompanied by reduced body mass, shortened body l

20 In the absence of FGF21, accumulation of inactivated fatty acids results i

21 Our study extends the work of the FGF21 actions on the neurocontrol of blood pressure regu

22 therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diab

23 In conclusion, FGF21 acts additively with GLP-1 to prevent insulinopeni

24 After a prolonged fast, FGF21 acts as an insulin sensitizer to overcome the peri

25 induces muscle atrophy, but via secretion of FGF21 acts distally to modulate whole-body metabolism.

26 tyrate (3-HIB), fibroblast growth factor 21 (FGF21), adiponectin, and nonesterified fatty acids (NEFA

27 rate of glucose disposal, and plasma 3-HIB, FGF21, adiponectin, and NEFA concentrations, under basal

28 DIO FGF21 liver-specific knockout, but not FGF21 adipose-specific knockout, mice have increased ins

29 in mediating favorable metabolic effects of FGF21 administration in DIOs housed at 80 degrees F or 7

30 thermore, pre-clinical studies revealed that FGF21 administration leads to improvement in the metabol

31 ake in interscapular BAT (iBAT) of DIOs upon FGF21 administration.

32 mice, which show an increase in circulating FGF21 after only 6 hours, human subjects did not have a

33 FGF21 also regulates fatty acid metabolism in mice consu

34 e treated 6-week-old Bscl2(-/-) mice with an FGF21 analog (LY2405319) for a period of 28 days.

35 We used native-FGF21 and a long-acting FGF21 (PF-05231023), to determin

36 mma while leading to increased expression of FGF21 and adipoQ.

37 xpression of the genes encoding the myokines FGF21 and GDF15.

38 r as an organ that integrates the actions of FGF21 and provide metabolic benefits of FGF21 in Zucker

39 owever, FGF21 was not elevated in serum, and FGF21 and UCP1 mRNAs were not induced in liver or brown

40 ning activators fibroblast growth factor 21 (FGF21) and SIRT1.

41 serum levels of fibroblast growth factor 21 (FGF21), and activation of signaling pathways in adipose

42 However, the interplay between adiponectin, FGF21, and resistin signaling pathways during the onset

43 the metabolic benefit of AHR and established FGF21 as a direct transcriptional target of AHR.

44 These data establish FGF21 as a fasting-induced hormone in humans and indicat

45 Unbiased gene profiling studies revealed Fgf21 as a key negatively regulated Dnmt3a target gene i

46 We identified the endocrine hormone FGF21 as a mediator for the metabolic benefit of AHR and

47 We therefore establish Fgf21 as a novel gene target of Fenretinide signalling v

48 fied betaKlotho, an essential coreceptor for FGF21, as a direct target gene of Rev-erbalpha in white

49 during fasting via GRalpha and the PPARalpha-FGF21 axis that reduces fat burning.

50 gh an NEAA insufficiency-induced liver NUPR1/FGF21 axis.

51 As the critical co-receptor of FGF21, beta-klotho (klb) significantly expressed on the

52 ry, activation of hepatic AMPK/sirtuin-1 and FGF21/beta-klotho signaling pathways combined with down-

53 s such as HDL cholesterol, free fatty acids, FGF21, bilirubin, and lactate depend on the microbiome.

54 eins, including fibroblast growth factor 21 (FGF21), bone morphogenetic protein 8b (BMP8b), growth di

55 tein restriction, and requires both UCP1 and FGF21 but is independent of changes in food intake.

56 Interestingly, the transactivation of FGF21 by AHR contributed to both hepatic steatosis and s

57 ic and diet-induced mouse models of obesity, FGF21 can attenuate obesity-associated morbidities.

58 Consistent with this, Fgf21 can rescue Dnmt3a-mediated insulin resistance, and

59 P-mediated decrease in 3-HIB and increase in FGF21 concentration in plasma.

60 micromol/L) and the grand median [quartiles] FGF21 concentration increased (from 178 [116, 217] to 50

61 ene expression in muscle and increased serum FGF21 concentration.

62 -induced hormone in humans and indicate that FGF21 contributes to the late stages of adaptive starvat

63 Thus, FGF21 corrects hyperglycemia in diabetic mice independen

64 < .0002; for PP diet P < .0002); decrease in FGF21 correlated with loss of hepatic fat.

65 y fat along with PEG-leptin and exendin-4 or FGF21 cotreatment.

66 Serum level of FGF21 decreased by 50% in each group (for AP diet P < .0

67 However, the FGF21-dependent increase in UCP1 and energy expenditure

68 energy expenditure and Ucp1 expression in an FGF21-dependent manner, neither LP diet nor the deletion

69 FGF21 depletion exacerbated alcohol-induced hepatic stea

70 g FGF21 treatment in LIRKO mice, even though FGF21 did not reduce gluconeogenesis in these animals.

71 one induction, demonstrating that endogenous FGF21 does not drive starvation-mediated ketogenesis in

72 sed circulating fibroblast growth factor 21 (FGF21), elevated Fgf21 mRNA and protein solely in the he

73 The AHR-FGF21 endocrine signaling pathway establishes AHR as a p

74 However, whether FGF21 enhances insulin sensitivity under physiologic con

75 FGF21 exerts profound metabolic effects in Siberian hams

76 pharmacological activation of HRI increased Fgf21 expression and reduced lipid-induced hepatic steat

77 FGF21 expression and secretion as well as the associated

78 omeostasis, partly through the regulation of FGF21 expression and signaling.

79 Enhanced Fgf21 expression attenuated tunicamycin-induced endoplas

80 vo agonist activation of AHR reduces hepatic Fgf21 expression during a fast.

81 a small-molecule ISR activator that promoted Fgf21 expression in cell-based screens and by implicatio

82 Of note, increased Fgf21 expression in mice fed a high-fat diet or hepatocy

83 RNA analysis demonstrated that HRI regulates Fgf21 expression in primary hepatocytes.

84 We found that FGF21 expression in thymus declines with age and is indu

85 These results reveal that alcohol-induced FGF21 expression is a hepatic adaptive response to lipid

86 Here, we demonstrated that hepatic FGF21 expression is induced by dietary protein restricti

87 Here, we explore the role of AHR in hepatic Fgf21 expression through the use of a conditional, hepat

88 FGF21 expression was also significantly increased in liv

89 The link between the ISR and FGF21 expression was further reinforced by the identific

90 eased endogenous retinoic acid biosynthesis, Fgf21 expression was increased, whereas acute pharmacolo

91 Increased Fgf21 expression was observed in the livers of PPARbeta/

92 Enhanced muscle FGF21 expression was reflected by elevated circulating F

93 Hepa-1 cells ablates potent ER stress-driven Fgf21 expression, and pre-treatment with AHR antagonist

94 x) mice exhibit a 4-fold increase in hepatic Fgf21 expression, as well as elevated expression of the

95 glucose-, and ER stress-driven induction of FGF21 expression, indicating the effect is not mouse-spe

96 glucagon plus insulin to stimulate ATF4 and FGF21 expression.

97 ability of glucagon plus insulin to increase FGF21 expression.

98 he ability of glucagon to stimulate ATF4 and FGF21 expression.

99 ivity suppressed CDCA regulation of ATF4 and FGF21 expression.

100 c PPARalpha and fibroblast growth factor 21 (FGF21) expression and lower serum FGF21 levels, which ar

101 lpha)-dependent fibroblast growth factor 21 (FGF21) expression in the liver.

102 ver metabolites in DIOs, we demonstrate that FGF21 favorably alters liver metabolism.

103 A low BCAA diet transiently induces FGF21 (fibroblast growth factor 21) and increases energy

104 ion of the energy balance regulating hormone FGF21 (fibroblast growth factor 21).

105 genic enzyme HMGCS2 and the secreted protein FGF21 (fibroblast growth factor 21).

106 e given continuous subcutaneous infusions of FGF21 for 4 weeks while on an MCD diet had reduced steat

107 nd secretion of fibroblast growth factor 21 (FGF21) from skeletal muscle, resulting in increased meta

108 Moreover, many key aspects of FGF21 function in mice have been identified in the conte

109 Genetic gain of FGF21 function in mice protects against age-related thym

110 Conversely, loss of FGF21 function in middle-aged mice accelerated thymic ag

111 esting a possible evolutionary divergence in FGF21 function.

112 se data are compatible with the concept that FGF21 functions physiologically as an insulin sensitizer

113 ly, our results suggest that transfer of the FGF21 gene could be considered a promising approach for

114 ean mice revealed that mice transferred with FGF21 gene displayed suppressed lipogenesis in the liver

115 ines; the MCK-Plin5 mice have 80-fold higher FGF21 gene expression in muscle and increased serum FGF2

116 interacts with insulin to stimulate hepatic FGF21 gene expression.

117 n suppressed the ability of CDCA to increase FGF21 gene expression.

118 in skeletal muscle drives expression of the FGF21 gene in fast-twitch fibers and is metabolically pr

119 Transfer of the FGF21 gene in HFD-induced obese mice greatly increased t

120 nism by which glucagon and insulin increased FGF21 gene transcription in primary hepatocyte cultures.

121 Mechanistic studies on the effects of FGF21 gene transfer in lean mice revealed that mice tran

122 In this study, we evaluated the effects of FGF21 gene transfer on C57BL/6 mice fed a high fat diet

123 ription factor 4 (ATF4) binding sites in the FGF21 gene.

124 FGF21 has been proposed as a novel therapeutic for metab

125 Fibroblast growth factor 21 (FGF21) has been identified as a facilitator of cold-indu

126 Fibroblast growth factor 21 (Fgf21) has emerged as a potential plasma marker to diagn

127 Fibroblast growth factor 21 (FGF21) has emerged as an important beneficial regulator

128 ess, suggesting that LP-induced increases in FGF21 impact metabolic but not thermogenic endpoints.

129 FGF21 improved glucose tolerance and liver insulin sensi

130 his was achieved by investigating effects of FGF21 in aged hamsters, which is associated with reduced

131 Fenretinide normalised elevated levels of FGF21 in both high-fat diet-induced obese mice and in ge

132 Decreased hepatic and circulating levels of FGF21 in fasted SIRT1 LKO mice were associated with redu

133 We sought to determine the role of FGF21 in hepatic steatosis in mice exposed to chronic al

134 and correlated negatively with expression of FGF21 in human adipose tissue.

135 re, we explored the dynamics and function of FGF21 in human volunteers during a 10-day fast.

136 tigate the potential antidiabetic actions of FGF21 in insulin-deficient Gcgr(-/-) mice, an FGF21-neut

137 However, disrupting FGF21 in ksr2(-/-) mice does not normalize mass, length,

138 on analysis showed that fasting up-regulated FGF21 in livers of control mice but not in SIRT1 LKO mic

139 n acute cold exposure, indicating a role for FGF21 in maintaining normothermia, possibly via activati

140 Here we demonstrate that the actions of FGF21 in mouse adipose tissue, but not in liver, are mod

141 gh proteolytic cleavage of recombinant human FGF21 in preclinical species has been observed previousl

142 deletion of Fap stabilized recombinant human FGF21 in serum.

143 Hepatic overexpression of FGF21 in SIRT1 LKO mice increased the expression of gene

144 tudy not only sheds new light on the role of FGF21 in systems metabolism, but also on the ways our bo

145 demonstrated a novel regulatory function of FGF21 in the baroreflex afferent pathway (the nucleus tr

146 the beneficial effects of a novel mimetic of FGF21 in the LD state are a consequence of increased adi

147 n of glutamine or knockdown of PGC-1alpha or FGF21 in the liver suppressed the behavioral and metabol

148 1) were used to determine the involvement of FGF21 in the metabolic effect of AHR.

149 s of FGF21 and provide metabolic benefits of FGF21 in Zucker rats and DIOs.

150 f liver-derived fibroblast growth factor 21 (FGF21) in both lean and obese mice.

151 ulating hormone fibroblast growth factor 21 (FGF21) in the molecular mechanism regulating CYP3A4 expr

152 ption factor (ATF) 4, which is essential for Fgf21-induced expression.

153 essary and adequate for NUPR1 and subsequent FGF21 induction and secretion in hepatocytes in vitro an

154 Moreover, we determined that FGF21 induction was associated with decreased thermogene

155 FGF21 stimulation (causing varied levels of FGF21 induction) and Akt activation.

156 manner, neither LP diet nor the deletion of Fgf21 influenced sensitivity to acute cold stress.

157 Collectively, FGF21 integrates metabolic and immune systems to prevent

158 Collectively, these findings illustrate that FGF21 is a critical mediator of the effects of dietary M

159 FGF21 is a key metabolic regulator modulating physiologi

160 FGF21 is a secreted protein that plays critical roles in

161 FGF21 is a stress-induced hormone with potent anti-obesi

162 FGF21 is an atypical member of the FGF family that funct

163 Fgf21(-/-) mice were used to test whether FGF21 is an essential mediator of the physiological effe

164 FGF21 is being pursued as a therapeutic target for diabe

165 typically not expressed in skeletal muscle, FGF21 is induced in situations of muscle stress, particu

166 The biology of FGF21 is intrinsically complicated owing to its diverse

167 ntent in Fgf21(-/-) mice, demonstrating that Fgf21 is necessary for betaine's beneficial effects.

168 sly, the regulation of endogenously produced FGF21 is not well understood.

169 In mice, FGF21 is rapidly induced by fasting, mediates critical a

170 work established that hepatic expression of FGF21 is robustly increased by MR.

171 FGF21 is thought to act on its target tissues, including

172 Fibroblast growth factor 21 (FGF21) is a hepatokine that regulates glucose and lipid

173 Fibroblast growth factor 21 (FGF21) is a peptide hormone that is synthesized by sever

174 Fibroblast growth factor 21 (FGF21) is an important regulator of the fasting and feed

175 Fibroblast growth factor-21 (FGF21) is closely related to various metabolic and cardi

176 y, both of which were largely abolished upon FGF21 knockdown.

177 Male FGF21 knockout (FGF21 KO) and control (WT) mice were div

178 C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine

179 Male FGF21 knockout (FGF21 KO) and control (WT) mice were divided into groups

180 FGF21-KO mice given continuous subcutaneous infusions of

181 te inflammation and fibrosis were reduced in FGF21-KO mice given FGF21, similar to those of wild-type

182 Wildtype, Ucp1-KO and Fgf21-KO mice were placed on control and low protein (LP

183 C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine- and choline-de

184 mass, length, or bone density and content in fgf21(-/-)ksr2(-/-) mice.

185 FGF21 level appears to be a marker of metabolic improvem

186 The plasma Fgf21 level significantly correlated with intrahepatic t

187 cerebroventricular resistin increased plasma FGF21 levels and downregulated its receptor components i

188 The repression of FGF21 levels by Fenretinide occurs by reduced binding of

189 Importantly, we found that circulating FGF21 levels correlated with BAT activity during acute c

190 hibitor acutely increased circulating intact FGF21 levels in cynomolgus monkeys.

191 In conclusion, our results demonstrate that FGF21 levels in humans are related to BAT activity, sugg

192 The up-regulated Fgf21 levels in NAFLD were implied to be a protective re

193 ession was reflected by elevated circulating FGF21 levels in the patients, and robust FGF21 secretion

194 Here we studied plasma FGF21 levels in two cohorts of human subjects, in whom B

195 Additionally, FGF21 levels increased after ketone induction, demonstra

196 In humans, circulating FGF21 levels increased dramatically following 28 days on

197 c MKP-1 exhibit reduced circulating IL-6 and FGF21 levels that were associated with impaired skeletal

198 data indicate that dietary betaine increases Fgf21 levels to improve metabolic health in mice and sug

199 At the molecular level, elevated plasma Fgf21 levels were associated with dysregulated metabolic

200 iver, and both baseline and LP-induced serum FGF21 levels were reduced in mice lacking the eIF2alpha

201 In addition, FGF21 levels were related to the change in core temperat

202 factor 21 (FGF21) expression and lower serum FGF21 levels, which are two proteins known to increase d

203 is a potential target for regulating hepatic FGF21 levels.

204 ased BAT activity in parallel with increased FGF21 levels.

205 pharmacological retinoid treatment decreased FGF21 levels.

206 a benign stage of NAFLD, the elevated plasma Fgf21 likely indicated vulnerability to metabolic stress

207 DIO FGF21 liver-specific knockout, but not FGF21 adipose-spe

208 sulin resistance, and DNA methylation at the FGF21 locus was elevated in human subjects with diabetes

209 In LD hamsters with increased adiposity, FGF21 lowered body weight as a result of both reduced da

210 are related to BAT activity, suggesting that FGF21 may represent a novel mechanism via which BAT acti

211 he FGF21 promoter (-2070/+117) and levels of FGF21 messenger RNA and protein in HepG2 cells.

212 The MCD diet increased hepatic levels of FGF21 messenger RNA more than 50-fold and serum levels 1

213 Fgf21(-/-) mice were used to test whether FGF21 is an es

214 glucose homeostasis and liver fat content in Fgf21(-/-) mice, demonstrating that Fgf21 is necessary f

215 ivo insulin sensitivity in wild-type than in Fgf21(-/-) mice, particularly in heart and inguinal WAT.

216 a negative effect of MR on energy intake in Fgf21(-/-) mice.

217 sponse genes in liver was not compromised in Fgf21(-/-) mice.

218 in WAT and brown adipose tissue were lost in Fgf21(-/-) mice.

219 These findings suggest that 3-HIB and FGF21 might be involved in protein-mediated insulin resi

220 r study demonstrates the efficacy of a novel FGF21 mimetic in hamsters, but reveals attenuated effect

221 glucose tolerance and a reduction in hepatic Fgf21 mRNA and circulating FGF21.

222 ibroblast growth factor 21 (FGF21), elevated Fgf21 mRNA and protein solely in the heart, and upregula

223 A4 expression, circulating FGF21, or hepatic FGF21 mRNA levels were elevated.

224 FGF21 neutralization caused a decline in glucose toleran

225 GF21 in insulin-deficient Gcgr(-/-) mice, an FGF21-neutralizing antibody was administered prior to or

226 ance, but these effects were not observed in Fgf21-null mice.

227 The increase in FGF21 occurs mainly in muscles with a predominance of fa

228 nimals with reduced adiposity, the effect of FGF21 on body weight, caloric intake and fat oxidation w

229 F or 72 degrees F, the favorable effects of FGF21 on BW and glucose excursion were fully retained in

230 Administration of recombinant FGF21 or transient hepatic overexpression of FGF21 resul

231 ls with lower CYP3A4 expression, circulating FGF21, or hepatic FGF21 mRNA levels were elevated.

232 Importantly, FGF21 overexpression reduced intrathymic lipid, increase

233 iver and Huh7 cells after FGF21 treatment or FGF21 overexpression.

234 We used native-FGF21 and a long-acting FGF21 (PF-05231023), to determine the contribution of li

235 d delineate the ever-expanding complexity of FGF21 physiology.

236 In the liver, FGF21 plays an important role in the regulation of fatty

237 FGF21 production was impaired in CREBH-deficient mice, a

238 ncreased the transcriptional activity of the FGF21 promoter (-2070/+117) and levels of FGF21 messenge

239 The Fgf21 promoter contains several putative dioxin response

240 concordant changes in DNA methylation at the Fgf21 promoter region.

241 educed binding of RARalpha and Pol-II at the Fgf21 promoter.

242 An FGF21-PXR signaling pathway may be involved in decreased

243 nalyses of adipose tissue, expression of the FGF21 receptor cofactor beta-klotho was associated with

244 ation of miR-34a increased expression of the FGF21 receptor components, FGFR1 and betaKL, and also th

245 Moreover, the expressions of FGF21 receptors were aberrantly down-regulated in HFD ra

246 In conclusion, plasma levels of Fgf21 reflect liver fat accumulation and dysregulation o

247 In white adipose tissue (WAT), FGF21 regulates aspects of glucose metabolism, and in su

248 FGF21 regulates fatty acid activation and oxidation in l

249 ptor (PPAR) beta/delta deficiency in hepatic FGF21 regulation.

250 Certain PPARalpha target genes such as Fgf21 remain repressed in the fetal liver and become PPA

251 pothalamus and peripheral tissues, promoting FGF21 resistance.

252 t impairs adiponectin signaling and promotes FGF21 resistance.

253 FGF21 or transient hepatic overexpression of FGF21 resulted in reduced liver CYP3A4 luciferase report

254 xposed to alcohol received recombinant human FGF21 (rhFGF21) in the last 5 days.

255 ntraperitoneal infusion of recombinant human FGF21 (rhFGF21) on the dysregulated systolic blood press

256 associated with declining expression of Klb, Fgf21's crucial co-receptor, which suggests a resistance

257 ing FGF21 levels in the patients, and robust FGF21 secretion could be recapitulated by respiratory ch

258 Blocking canonical FGF21 signaling by pharmacological inhibition of MEK1 ki

259 Targeting FGF21 signaling could be a novel treatment approach for

260 lish Rev-erbalpha as a specific modulator of FGF21 signaling in adipose tissue.

261 ce through the impairment of adiponectin and FGF21 signaling.

262 fibrosis were reduced in FGF21-KO mice given FGF21, similar to those of wild-type mice.

263 betaKL, and also that of SIRT1, resulting in FGF21/SIRT1-dependent deacetylation of PGC-1alpha and in

264 ecific pathways in the liver responsible for FGF21 stimulation (causing varied levels of FGF21 induct

265 ever, fasting does not consistently increase FGF21, suggesting a possible evolutionary divergence in

266 cient mice, and adenoviral overexpression of FGF21 suppressed adipose tissue lipolysis and improved h

267 ssion, as well as elevated expression of the FGF21-target gene Igfbp1 Furthermore, in vivo agonist ac

268 ein solely in the heart, and upregulation of FGF21-target genes involved in thermogenesis and fatty a

269 E-cadherin and fibroblast growth factor 21 (FGF21), targets of sirtuin-1, and beta-klotho, which can

270 n of a myokine, fibroblast growth factor 21 (FGF21), that stimulates energy consumption and prevents

271 r, the direct targets and mechanisms linking FGF21 to blood pressure control and hypertension are sti

272 intact liver insulin action is required for FGF21 to control hepatic lipid metabolism.

273 effects were underpinned by the inability of FGF21 to increase the expression of key thermogenic gene

274 cision of iBAT (X-BAT) and administration of FGF21 to mice housed at 80 degrees F or 72 degrees F, th

275 nstrate that glucagon plus insulin increases FGF21 transcription by stimulating ATF4 expression and t

276 lts also demonstrate that CDCA regulation of FGF21 transcription is mediated at least partially by an

277 ated that glucagon plus insulin induction of FGF21 transcription was conferred by two activating tran

278 to the CYP3A4 proximal promoter was found in FGF21-treated Huh7 cells.

279 Interestingly, FGF21 treatment exerted an antistress effect on SKD cell

280 Our data demonstrate that FGF21 treatment improves the metabolic profile of Bscl2(

281 glycemia was completely normalized following FGF21 treatment in LIRKO mice, even though FGF21 did not

282 FGF21 treatment increased adiponectin plasma levels and

283 observed in mouse liver and Huh7 cells after FGF21 treatment or FGF21 overexpression.

284 de-repression of CYP3A4 mRNA expression with FGF21 treatment.

285 man subjects did not have a notable surge in FGF21 until 7 to 10 days of fasting.

286 Notably, elevated plasma Fgf21 was associated with declining expression of Klb, F

287 Increased Fgf21 was associated with enhanced protein levels in the

288 FGF21 was found to be expressed in pancreatic beta- and

289 oreover, Fenretinide-mediated suppression of FGF21 was independent of body weight loss or improved he

290 However, FGF21 was not elevated in serum, and FGF21 and UCP1 mRNA

291 FGF21 was overexpressed in SIRT1 LKO mice using an adeno

292 Strikingly, Fgf21 was the most downregulated hepatic gene.

293 Fibroblast growth factor 21 (FGF21) was shown to improve metabolic homeostasis, at le

294 LP-induced increases in FGF21 were associated with increased phosphorylation of

295 Consequently, the effects of FGF21 were markedly enhanced in the white adipose tissue

296 n RNA targeting fibroblast growth factor 21 (FGF21) were used to determine the involvement of FGF21 i

297 e documented metabolic beneficial effects of FGF21, which include weight loss and improved glycemia.

298 is activated by TG accumulation and induces FGF21, which suppresses adipose tissue lipolysis, amelio

299 Neutralization of FGF21, while concurrently blocking the GLP-1 receptor wi

300 ocesses underlying the association of plasma Fgf21 with NAFLD, we explored the liver transcriptome da